Barrington lowered the firm’s price target on Stoneridge (SRI) to $16 from $20-$25 and keeps an Outperform rating on the shares. The company’s Q3 came in weaker than expected and 2024 guidance was reduced as market challenges continue, the analyst tells investors in a research note.